NEW YORK—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing and developing the Optejet device for use both in connection with its own mydriasis product and product candidates for presbyopia and pediatric progressive myopia, has announced the expansion of its U.S. manufacturing facilities in Redwood City, California, and Reno, Nevada. The Redwood City facility, which was announced operational last year, focuses primarily on Optejet pharmaceutical manufacturing finishing operations, including drug loading, labeling, and packaging prior to distribution.

The new Reno facility will focus on device manufacturing and boasts over 10,000 square feet of space to better serve the growing needs of the company.

"We are pleased to continue executing on our manufacturing strategy by expanding our capabilities in Redwood City and Reno," said Michael Rowe, CEO of Eyenovia. "Our new and upgraded facilities will allow us to continue the development of our existing and future products, better serving our licensees and partners and continuing to advance our mission of improving the delivery of topical ophthalmic therapies."

Eyenovia, Inc. is a commercial stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics. Eyenovia is currently focused on the commercialization of Mydcombi for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression.